Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24857442 | 0.83 | GAA (0.55) | GAACDK1CCNB1ACHECA2 | |
| SCHEMBL18056167 | 0.83 | GAA (0.55) | GAACDK1CCNB1ACHECA2 | |
| SCHEMBL5793535 | 0.82 | GAA (0.65) | GAACDK1CCNB1ACHECA2 | |
| SCHEMBL20315376 | 0.82 | GAA (0.65) | GAACDK1CCNB1ACHECA2 | |
| SCHEMBL8325931 | 0.82 | GAA (0.65) | GAACDK1CCNB1ACHECA2 | |
| SCHEMBL26829174 | 0.81 | LGALS8 (0.39) | GAACDK1CCNB1ACHEPTPN1 | |
| SCHEMBL25949411 | 0.79 | LGALS8 (0.39) | GAACDK1CCNB1PTPN1LGALS8 | |
| Melibiose SCHEMBL21356841 | 0.79 | GAA (0.61) | GAACDK1CCNB1ACHECA2 | |
| Melibiose SCHEMBL21356838 | 0.79 | GAA (0.61) | GAACDK1CCNB1ACHECA2 | |
| Melibiose SCHEMBL21114348 | 0.79 | GAA (0.61) | GAACDK1CCNB1ACHECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | SCOTT, JOHN KIM, JR. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210998-A1 | METHODS FOR THE CONJUGATION OF ANTHRACYCLINES TO CARBOHYDRATE POLYMERIC CARRIERS | TOP1, ALG1, GNE | GAA 171/4885CDK1 578/4885CCNB1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.